Azenta (AZTA) Expected to Announce Earnings on Tuesday

Azenta (NASDAQ:AZTA) is expected to be posting its Q3 2026 results before the market opens on Tuesday, August 4th. Analysts expect Azenta to announce earnings of $0.1138 per share and revenue of $149.2380 million for the quarter. Interested persons may visit the the company’s upcoming Q3 2026 earning summary page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 8:30 AM ET.

Azenta (NASDAQ:AZTA) last announced its earnings results on Wednesday, May 6th. The company reported ($0.04) earnings per share for the quarter, missing the consensus estimate of $0.12 by ($0.16). The firm had revenue of $144.79 million during the quarter, compared to analysts’ expectations of $148.47 million. Azenta had a negative net margin of 30.49% and a positive return on equity of 1.23%. Azenta’s revenue for the quarter was up 1.4% compared to the same quarter last year. During the same quarter last year, the company posted $0.01 earnings per share.

Azenta Stock Up 2.4%

Shares of Azenta stock traded up $0.65 during trading hours on Tuesday, hitting $28.17. 88,673 shares of the company’s stock traded hands, compared to its average volume of 934,844. Azenta has a twelve month low of $15.93 and a twelve month high of $41.73. The company has a market cap of $1.30 billion, a PE ratio of -7.12 and a beta of 1.37. The stock has a 50 day simple moving average of $23.92 and a 200-day simple moving average of $25.99.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd raised its stake in Azenta by 2,067.6% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 802 shares of the company’s stock valued at $27,000 after purchasing an additional 765 shares during the period. Osaic Holdings Inc. raised its position in Azenta by 44.9% during the second quarter. Osaic Holdings Inc. now owns 1,242 shares of the company’s stock valued at $39,000 after buying an additional 385 shares during the period. Van ECK Associates Corp grew its position in Azenta by 141.2% during the fourth quarter. Van ECK Associates Corp now owns 1,585 shares of the company’s stock valued at $53,000 after purchasing an additional 928 shares in the last quarter. Quantbot Technologies LP purchased a new stake in Azenta in the 3rd quarter worth approximately $57,000. Finally, Tower Research Capital LLC TRC boosted its stake in shares of Azenta by 472.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 3,002 shares of the company’s stock valued at $92,000 after buying an additional 2,478 shares during the period. 99.08% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on AZTA shares. Needham & Company LLC reduced their price target on shares of Azenta from $44.00 to $33.00 and set a “buy” rating for the company in a report on Wednesday, May 6th. Weiss Ratings raised shares of Azenta from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 15th. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Azenta presently has a consensus rating of “Hold” and an average target price of $40.40.

Azenta Company Profile

Azenta, Inc (NASDAQ: AZTA) is a life sciences technology company specializing in sample management, cryogenic storage and genomic services for research and clinical applications. Formerly the Life Sciences division of Brooks Automation, Azenta provides integrated solutions that enable customers to store, track and analyze biological samples with high levels of automation, data integrity and efficiency. Its offerings span automated storage systems, biorepository management software and end?to?end sample tracking workflows.

In addition to hardware and informatics platforms for sample storage, Azenta’s Genomics business delivers next?generation sequencing (NGS), DNA synthesis, and molecular biology services.